Dave:
Yes, it's in the clinic. The release was describing human clinical work. This is the GM-CSF stuff that I was referring to here......
techstocks.com
Relevant excerpt from the CEGE 10-K.......
1.10 "Current Clinical Trials" shall mean collectively the following two
(2) clinical trials that are currently in progress as of the Effective Date: (i)
"Study of Vaccination with Autologous, Lethally Irradiated Non-Small Cell Lung
Carcinoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human
GM-CSF," conducted by Glenn Dranoff, M. D., at Dana-Farber Cancer Institute; and
(ii) "A Phase I/II Study of Allogeneic Human GM-CSF Transduced Cancer Vaccines
in Patients with Metastatic Prostate Carcinoma," conducted by Jonathan Simons,
M.D., at Johns Hopkins Oncology Center, in each case as such studies may be
modified from time to time by the Development Committee. Notwithstanding
anything herein to the contrary, it is understood that, [*]
I'm a little confused, however, as the release describes a patient-specific (not "allogeneic") approach. I guess that "modified from time to time by the Development Committee" has come into play since the 10-K was written??
Yes, GZMO has had good news up the WZOO..... the ATIII article in Science, the $millions and gift programs from CEGE, the Id1/Id3 manuscript in Nature, and now the prostate results...... and the shares have done zip. Brought to you courtesy of John Holaday's BSHT.
Rick |
